Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Macular Edema
Interventions: AR-1105-CF1, AR-1105-CF2; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more

Conditions: Retinitis Pigmentosa
Interventions: human retinal progenitor cells, Mock injection; Biological · Other
Lead sponsor: jCyte, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 12
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 9 more

Conditions: Dementia, Dementia Alzheimer Type
Interventions: Not listed
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Coconut Creek, Florida

Conditions: Age Related Macular Degeneration
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 470 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 4
States / cities: Atlanta, Georgia • Bethesda, Maryland • Durham, North Carolina + 1 more

Conditions: Central Serous Chorioretinopathy
Interventions: Intravitreal Aflibercept Injection; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Retinoschisis, X-Linked
Interventions: RS1 AAV Vector; Biological
Lead sponsor: VegaVect, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Macular Edema
Interventions: OXU-001, Semi-automated suprachoroidal illuminated microcatheter, Ozurdex® Ophthalmic Intravitreal Implant; Drug · Device
Lead sponsor: Oxular Limited; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Phoenix, Arizona • Clearwater, Florida • Oak Forest, Illinois + 5 more

Conditions: Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma
Interventions: SU011248; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Age-Related Macular Degeneration
Interventions: AG-013,958; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 30
States / cities: Mesa, Arizona • Oro Valley, Arizona • Phoenix, Arizona + 27 more

Conditions: Retinal Vascular Disease
Interventions: Swept-Source Optical Coherence Tomography; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Central Serous Chorioretinopathy
Interventions: Mifepristone, Placebo; Drug
Lead sponsor: Roger Goldberg, M.D., MBA; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Walnut Creek, California • Boston, Massachusetts

Conditions: Macular Degeneration
Interventions: Pazopanib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more

Conditions: Geographic Atrophy
Interventions: No intervention; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Pensacola, Florida • Chesterfield, Missouri • Charlotte, North Carolina + 8 more

Conditions: Macular Degeneration, Retinal Drusen
Interventions: Pascal Retinal Laser Photocoagulator; Device
Lead sponsor: Stanford University; Other
Eligibility: 60 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Age Related Macular Degeneration
Interventions: carbidopa-levodopa; Drug
Lead sponsor: Snyder, Robert W., M.D., Ph.D., P.C.; Individual
Eligibility: 50 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetic Retinopathy
Interventions: Aflibercept Injection; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Beverly Hills, California • Orlando, Florida • Winter Haven, Florida + 10 more

Conditions: Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD), Rod-Cone Dystrophy, Rod-Cone Disease, Retinal Degeneration, Cone-Rod Disease (C-RD), Cone-Rod Dystrophy
Interventions: OpCT-001; Biological
Lead sponsor: BlueRock Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes, Diabetes, Retinopathy, Neuropathy, Nephropathy, Blood Pressure, Cardiovascular Risk, Microvascular
Interventions: observational study; Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 12 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution; Drug
Lead sponsor: Nicole Fram M.D.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Retinoblastoma
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions: RGX-314; Genetic
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years and older
Enrollment: 865 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more

Conditions: Age Related Macular Degeneration
Interventions: RBM-007 Injectable Solution; Drug
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 50 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Macular Degeneration
Interventions: pazopanib eye drops, placebo, ranibizumab intravitreal injection; Drug · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 37
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Retinitis Pigmentosa
Interventions: Intravitreal autologous CD34+ cells; Biological
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

Dynamic Light Scattering Ocular Measurement in the Detection of Dementia

AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study

The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

Research on the Environment and Children's Health: Retinoblastoma

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa